Randomised comparison of anticoagulation control and monitoring with versus without laboratory-provided computerized decision support
| ISRCTN | ISRCTN27244875 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN27244875 |
| Protocol serial number | N/A |
| Sponsor | Ontario Program for Optimal Therapeutics (Canada) |
| Funder | Ontario Program for Optimal Therapeutics (Canada) |
- Submission date
- 08/11/2005
- Registration date
- 25/11/2005
- Last edited
- 14/09/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Michael Paterson
Scientific
Scientific
ICES
G106-2075 Bayview Ave.
Toronto, Ontario
M4N 3M5
Canada
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Cluster-randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | Laboratory-provided computerized decision support will improve anticoagulation control relative to usual care |
| Ethics approval(s) | Yes, August 2001 |
| Health condition(s) or problem(s) studied | Various |
| Intervention | Anticoagulation control and monitoring with versus without laboratory-provided computerized decision support (CDS) |
| Intervention type | Other |
| Primary outcome measure(s) |
1. Acceptability of the CDS service, as assessed by the proportion of physicians who would continue to use it if offered |
| Key secondary outcome measure(s) |
Hemorrhagic and thromboembolic events requiring hospital attendance |
| Completion date | 30/06/2003 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 380 |
| Key inclusion criteria | Physicians: 1. Family or general practitioner 2. Full-time office practice 3. Practice address within study laboratory catchment area 4. At least 3 eligible patients willing to participate Patients: 1. On long-term warfarin therapy 2. Using the study laboratory for international normalized ratio (INR) tests and expecting to continue to do so for at least 12 months |
| Key exclusion criteria | None |
| Date of first enrolment | 01/01/2002 |
| Date of final enrolment | 30/06/2003 |
Locations
Countries of recruitment
- Canada
Study participating centre
ICES
Toronto, Ontario
M4N 3M5
Canada
M4N 3M5
Canada
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
